Senior Vice President, Chief Financial Officer · Theravance Biopharma, Inc. (TBPH)

Aziz Sawaf

A named executive officer of Theravance Biopharma in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,450,777

Salary $462,375Stock awards $790,624

FY2023: $1,386,700

3rd of 3 named executive officers at Theravance Biopharma by FY2024 total.

3 named officers on file for Theravance Biopharma, FY2024

Aziz Sawaf’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Theravance Biopharma’s whole pay program stands against its peers

  • Theravance Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TBPH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Aziz Sawaf’s full pay file as a PDF — free

More than this page: up to 10 years of Aziz’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Aziz Sawaf compensation by year

Theravance Biopharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as Theravance Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$448,500$462,375
Bonus$9,000$0
Stock awards$803,200$790,624
Option awards$0$0
Non-equity incentive$126,000$197,000
Pension and deferred compensation$0$0
All other$0$777
Total$1,386,700$1,450,777

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Theravance Biopharma, Inc. DEF 14A filed April 10, 2025, accession 0001104659-25-033819, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Theravance Biopharma, Inc. filed document, accession 0001104659-25-033819. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2025.

$1.4M
$1.5M
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU45,000$423,450—
RSU37,500$352,875—
RSU20,000$196,039—
PSU20,833$196,039—
RSU17,500$164,675—
RSU6,562$61,748—
RSU2,500$23,525—
RSU625$5,881—

Per the Outstanding Equity Awards at Fiscal Year-End table in Theravance Biopharma, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

10 Form 4 lines since the FY2024 proxy (filed April 10, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-23Disposition to the issuer—23,439—0
2026-09-23Disposition to the issuer—108,436—23,439
2026-09-23Disposition to the issuer—204,966—131,875
2026-08-20Tax withholding—8,112$16.95336,841
2026-05-20Tax withholding—8,670$16.55344,953
2026-04-01Grant or award—37,500$0.00353,623
2026-02-20Tax withholding—20,672$19.66316,123
2025-11-20Tax withholding—18,627$17.90336,795

The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Theravance Biopharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Rick WinninghamChief Executive Officer$3,995,931
Brett GrimaudSenior Vice President, General Counsel & Secretary$1,481,494
Aziz Sawaf · this pageSenior Vice President, Chief Financial Officer$1,450,777

The full Theravance Biopharma compensation record

free company brief

This page is one person within Theravance Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Theravance Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Aziz Sawaf's compensation dossier · One-time report. No refunds.